Novo Nordisk A/S (NVO) Stock: Price, Forecast & Analyst Target
Novo Nordisk A/S (NVO) — MoonshotScore 91/100 (Exceptional band), calculated Oct 8, 2026. Price $38.18 (-0.21%), as of the Oct 8, 2026 trading session; market cap $170B. Expected results Nov 4, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Novo Nordisk A/S · NVO · NYSE · Healthcare · Drug Manufacturers - General
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint.
Price as of Oct 8, 2026
Key Statistics
MoonshotScore v2 · Novo Nordisk A/S (NVO)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, at a cheap price, though the balance sheet is only decent. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Growing; Momentum: Quiet.
- quarterly revenue $11.80B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 7 of 8
- Altman Z 3.65 · Piotroski F 6
Helping: business quality, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional |
The score was 91 in the stored Oct 7, 2026 snapshot and remains 91 in the current publication computed Oct 8, 2026 (0); the largest pillar moves were Momentum +2 and Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $38.18 | |
| Change on the day | -0.21% | |
| 52-week range | $35.12–$64.16 | |
| Market capitalisation | $170B | |
| Price / earnings (trailing) | 9.60 | |
| Shares traded on the day | 11.43M | |
| Beta (volatility vs the S&P 500) | 0.35 | |
| Dividends per share (last 12 months) | $1.80 | |
| Dividend yield (last 12 months) | 4.71% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We still expect a U.S. decision for CagriSema in obesity at the end of 2026, with a potential launch in 2027.
Martin Holst Lange · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Novo Nordisk A/S (NVO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 9, 2026, except a card that shows its own read date.
Watch the NVO film — every key number, told as a short cinematic story
~2 min · open the film
What is Novo Nordisk A/S (NVO), and what does it report?
Short answer · as of
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Novo Nordisk A/S (NVO) is listed on NYSE. Healthcare / Drug Manufacturers General SEC filing business address: Novo Alle DK 2880, Bagsvaerd Denmark, G7, 00000. It employs 68,794 people and is led by Maziar Mike Doustdar. In Q2 FY2026 it reported revenue of $11.80B and net income of $3.15B. The market values it at $170B.
What do the latest results show for Novo Nordisk A/S (NVO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $11.80B. Against analyst estimates the company has EPS beat 7 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $12.13B Aug 5, 2026
- Latest report · revenue estimate
- $10.89B Aug 5, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $12.13B | $10.89B | $0.9600 | $0.8200 |
| May 6, 2026 | $11.02B | $10.86B | $1.0400 | $0.8700 |
| Feb 3, 2026 | $12.50B | $12.13B | $1.0000 | $0.9000 |
| Nov 5, 2025 | $11.53B | $11.94B | $1.0200 | $0.7700 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $11.80B | $3.15B | $0.71 (diluted) |
| Q1 FY2026 | $14.55B | $7.30B | $1.64 (diluted) |
| Q4 FY2025 | $11.90B | $4.04B | $0.91 (diluted) |
| Q3 FY2025 | $11.27B | $3.01B | $0.68 (diluted) |
What are the financial strengths and risks for Novo Nordisk A/S (NVO)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. The distress and quality screens read Altman Z 3.65 · Piotroski F 6. Trailing ratios: ROE 59.1% · ROA 19.6% · current ratio 0.87 · earnings yield 10.4% · free-cash-flow yield 4.4%.
What should you watch next at Novo Nordisk A/S (NVO)?
Short answer · as of
The next earnings report is expected on Nov 4, 2026. Current published price targets run low $40.00 · high $47.00 · consensus $44.67 · median $47.00 against a quoted price of $38.18 (as of Oct 8, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We still expect a U.S. decision for CagriSema in obesity at the end of 2026, with a potential launch in 2027.
Martin Holst Lange ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Novo Nordisk A/S compare with its peers?
Short answer
Novo Nordisk A/S's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1169.93 Oct 8, 2026 | $1.09T | 98 5-pillar Oct 8, 2026 | |
| $59.58 Oct 8, 2026 | $122B | 92 5-pillar Oct 8, 2026 | |
| Novo Nordisk A/S (NVO) — this page | $38.18 | $170B | 91 |
| $256.48 Oct 8, 2026 | $618B | 90 5-pillar Oct 8, 2026 | |
| $46.54 Oct 8, 2026 | $93.2B | 88 5-pillar Oct 8, 2026 | |
| $158.78 Oct 8, 2026 | $245B | 86 5-pillar Oct 8, 2026 | |
| $407.44 Oct 8, 2026 | $220B | 86 5-pillar Oct 8, 2026 | |
| $40.23 Oct 8, 2026 | $96.6B | 86 5-pillar Oct 8, 2026 | |
| $143.11 Oct 8, 2026 | $272B | 84 5-pillar Oct 8, 2026 | |
| $272.42 Oct 8, 2026 | $481B | 79 5-pillar Oct 8, 2026 | |
| $142.40 Oct 8, 2026 | $352B | 75 5-pillar Oct 8, 2026 | |
| $27.82 Oct 8, 2026 | $159B | 68 5-pillar Oct 8, 2026 | |
| $218.43 Oct 8, 2026 | $32.3B | 68 5-pillar Oct 8, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $40.00 – $47.00
- Consensus target
- $44.67
- Median target
- $47.00
Consensus record · Captured .
Measured against a quoted price of $38.18 (as of Oct 8, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 7.4% Period end Jun 30, 2026
- Previous quarter · ownership
- 7.3% Prior to period end Jun 30, 2026
- Reporting holders
- 1,454 Period end Jun 30, 2026
- Previous quarter · holders
- 1,370 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Dodge & Cox | 20,397,110 |
| Loomis Sayles & Co L P | 18,594,352 |
| Franklin Resources INC | 13,041,109 |
| Susquehanna International Group, Llp | 12,009,200 |
| Price T Rowe Associates INC /Md/ | 11,704,719 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Novo Nordisk A/S (NVO)?
What Investors Ask About Novo Nordisk A/S (NVO) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why do insulin pens and Dose Check matter to Novo Nordisk?
They connect Novo Nordisk's medicines with drug delivery and dosing support. This makes the business more than a seller of pharmaceutical compounds, because devices and digital tools participate in how patients administer therapy.
What is the NVO stock price today?
The last price recorded on this page for Novo Nordisk A/S (NVO) is $38.18, as of the Oct 8, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NVO price target?
The analyst consensus price target for Novo Nordisk A/S (NVO) is $44.67 (range $40.00 to $47.00, median $47.00), per FMP data captured Oct 8, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does NVO pay a dividend?
Yes. Novo Nordisk A/S (NVO) shows a trailing 12-month dividend yield of 4.71%, as of Oct 8, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (57 figures)
The 57 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Martin Holst Lange (Aug 5, 2026): We still expect a U.S. decision for CagriSema in obesity at the end of 2026, with a potential launch in 2027. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Novo Alle DK 2880, Bagsvaerd Denmark, G7, 00000 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Novo Alle 1, Bagsvaerd, CR, 2880, DK". |
FMP — 45 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $38.18 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-09T07:05:17.282Z. | |
px.change | Change on the day | -0.21% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $170B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-08. FMP quote timestamp: 2026-10-08T20:00:02.000Z. Captured from FMP at 2026-10-09T07:04:55.322Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 4, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.08 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $11.80B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $35.12–$64.16 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 9.60 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 11.43M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.35 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers General | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | |
id.employees | Employees | 68,794 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Maziar Mike Doustdar | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | $3.15B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $12.13B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $10.89B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | $0.9600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | $0.8200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_actual | Revenue · reported — report date 2026-05-06 | $11.02B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_estimated | Revenue · estimate — report date 2026-05-06 | $10.86B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_actual | EPS · reported — report date 2026-05-06 | $1.0400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_estimated | EPS · estimate — report date 2026-05-06 | $0.8700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.revenue_actual | Revenue · reported — report date 2026-02-03 | $12.50B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.revenue_estimated | Revenue · estimate — report date 2026-02-03 | $12.13B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.eps_actual | EPS · reported — report date 2026-02-03 | $1.0000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.eps_estimated | EPS · estimate — report date 2026-02-03 | $0.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_actual | Revenue · reported — report date 2025-11-05 | $11.53B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_estimated | Revenue · estimate — report date 2025-11-05 | $11.94B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_actual | EPS · reported — report date 2025-11-05 | $1.0200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_estimated | EPS · estimate — report date 2025-11-05 | $0.7700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $40.00 · high $47.00 · consensus $44.67 · median $47.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $40.00 – $47.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $44.67 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $47.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 7.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 7.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 1,454 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 1,370 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Dodge & Cox — shares in provider snapshot | 20,397,110 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Loomis Sayles & Co L P — shares in provider snapshot | 18,594,352 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Franklin Resources INC — shares in provider snapshot | 13,041,109 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Susquehanna International Group, Llp — shares in provider snapshot | 12,009,200 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 11,704,719 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-07 | |
fin.scores | Distress and quality screens | Altman Z 3.65 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-08 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 59.1% · ROA 19.6% · current ratio 0.87 · earnings yield 10.4% · free-cash-flow yield 4.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.80 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-09, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 4.71% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($12.13B) with the recorded estimate ($10.89B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.9600) with the recorded estimate ($0.8200) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 91 of 100 · Exceptional · pillars 98 / 63 / 69 / 76 / 44 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 91 (stored snapshot Oct 7, 2026) → 91 (current publication computed Oct 8, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-06.revenue_actual,earn.history.depth.2026-05-06.revenue_estimated,earn.history.depth.2026-05-06.eps_actual,earn.history.depth.2026-05-06.eps_estimated,earn.history.depth.2026-02-03.revenue_actual,earn.history.depth.2026-02-03.revenue_estimated,earn.history.depth.2026-02-03.eps_actual,earn.history.depth.2026-02-03.eps_estimated,earn.history.depth.2025-11-05.revenue_actual,earn.history.depth.2025-11-05.revenue_estimated,earn.history.depth.2025-11-05.eps_actual,earn.history.depth.2025-11-05.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.
ETFs that hold NVO
Funds in our ETF coverage that list NVO among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| The Obesity ETF (SLIM) | 19.95% | |
| Simplify Health Care ETF (PINK) | 4.66% |